The Expanding Landscape of Pharmaceutical Drug Modalities
Pharmaceutical drug development has long been described as a choice between two categories: small molecules and large molecules (biologics). For most of the twentieth century, this binary was adequate — synthetic chemical drugs on one side, protein-based biologics on the other. But the first quarter of the twenty-first century has shattered that simplicity. Antibody-drug conjugates bridge both categories. mRNA therapeutics are manufactured like synthetic nucleic acids but behave like biologics once inside cells. Oligonucleotide drugs (siRNA, ASO) have their own distinct chemistry, pharmacology, and regulatory pathway. PROTACs are small molecules that function as catalytic degraders rather than inhibitors. GLP-1 agonists — the world’s best-selling drug class in 2025 — are synthetic peptides occupying a space between classical small molecules and biologics. And biosimilars have created an entirely new regulatory and testing category for the post-patent biologic landscape.
Understanding these modalities — their distinct chemistries, development pathways, commercial applications, and analytical testing requirements — is essential for drug developers, contract research organizations, CMOs, and the contract laboratories that support them. ContractLaboratory.com connects pharmaceutical and biotechnology companies with accredited pharmacology and drug development laboratories and pharmaceutical and biopharmaceutical testing partners across the full spectrum of these modalities.
Pharmaceutical Modalities at a Glance
| Modality | Molecular weight | Production | Administration | Key examples | Regulatory path |
| Small molecules | <900 Da (typically <500 Da for oral drugs) | Chemical synthesis | Oral (pills, capsules); some IV | Ibuprofen, imatinib (Gleevec), oseltamivir (Tamiflu) | NDA (FDA); MAA (EMA) |
| Peptide drugs | ~500–10,000 Da | Solid-phase peptide synthesis; semi-synthetic modification | Injection or infusion; some oral formulations | Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro), insulin | NDA or BLA depending on structure and origin |
| Biologics (mAbs, proteins, vaccines) | ~15,000–150,000 Da (mAb ~150 kDa) | Living cells (bacteria, yeast, CHO mammalian) | Injection or infusion | Trastuzumab (Herceptin), adalimumab (Humira), pembrolizumab (Keytruda) | BLA (FDA); MAA (EMA) |
| Antibody-drug conjugates (ADCs) | ~150,000 Da (antibody) + payload; heterogeneous mixture | Biologic antibody production + chemical conjugation | IV infusion | Trastuzumab deruxtecan (Enhertu), sacituzumab govitecan (Trodelvy) | BLA (FDA); MAA (EMA) |
| mRNA therapeutics | ~250,000–2,500,000 Da (1,000–10,000+ nucleotides) | Cell-free enzymatic synthesis (in vitro transcription); LNP formulation | Injection or infusion | Comirnaty/Spikevax (COVID vaccines), mRNA-4157/V940 (cancer vaccine) | BLA (FDA); CAT/CHMP (EMA) |
| Oligonucleotides (siRNA, ASO) | ~7,000–25,000 Da (20–30 nucleotides) | Solid-phase synthesis (like small molecules) | Subcutaneous injection; intrathecal (some ASOs) | Patisiran/ONPATTRO (siRNA), inclisiran/Leqvio (siRNA), nusinersen/Spinraza (ASO) | NDA or BLA depending on structure; varies by region |
| Gene & cell therapies (ATMPs) | Viral vector, plasmid DNA, or modified cells — variable | Viral vector (AAV, lentiviral); cell culture; ex vivo cell modification | IV infusion; direct tissue injection; ex vivo (CAR-T) | Zolgensma (gene therapy), Kymriah/Yescarta (CAR-T) | BLA (FDA); ATMPs/CAT (EMA) |
| Biosimilars | Same as reference biologic | Biological production (independent manufacturer) | Same as reference biologic | Biosimilar adalimumab products (Hadlima, Hyrimoz, etc.) | BLA 351(k) (FDA); biosimilar application (EMA) |
Small Molecule Drugs
Small molecules are low molecular weight compounds — typically below 900 Da, with most orally bioavailable drugs below 500 Da — synthesized through organic chemistry. They are the foundation of the pharmaceutical industry, comprising the majority of all approved drugs by number and still dominant in terms of total patient prescriptions.
Lipinski’s Rule of Five and Oral Bioavailability
The foundational framework for predicting whether a small molecule will be orally bioavailable is Lipinski’s Rule of Five, published by Christopher Lipinski at Pfizer in 1997. A molecule is predicted to have acceptable oral bioavailability if it satisfies most of these criteria: molecular weight ≤500 Da; calculated logP (octanol-water partition coefficient) ≤5; number of hydrogen bond donors ≤5; number of hydrogen bond acceptors ≤10. Violations of two or more of these rules correlate with poor oral absorption. The Rule of Five is applied during lead optimization to filter compound libraries and guide synthetic modifications. It also explains why biologics — which violate all four criteria — cannot be given orally.
ADME Profiling in Small Molecule Development
ADME — Absorption, Distribution, Metabolism, and Excretion — characterizes how the body handles a drug and drives critical go/no-go decisions in small molecule development:
- Absorption: How much of the administered drug reaches systemic circulation. For oral drugs, it involves gut wall permeability (assessed by Caco-2 cell assays), efflux transporter interactions (P-gp, BCRP), and first-pass hepatic metabolism.
- Distribution: Volume of distribution (Vd) describes how widely the drug distributes in body tissues vs. blood. Highly lipophilic drugs have large Vd and may accumulate in fat tissue.
- Metabolism: Primarily hepatic, involving cytochrome P450 (CYP) enzymes. CYP inhibition and induction studies are critical for predicting drug-drug interactions. Metabolite identification by LC-MS/MS determines whether metabolites have pharmacological activity or safety concerns.
- Excretion: Renal (urine) and biliary (feces) elimination. Half-life (t½) and clearance determine dosing frequency.
High-throughput ADME screening using computational prediction (in silico), cell-based assays (in vitro), and animal studies (in vivo) is central to preclinical development and critical to avoiding late-stage attrition.
Beyond Classic Kinase Inhibitors: PROTACs and Targeted Protein Degraders
Traditional small-molecule drugs work by inhibiting or blocking their target protein. PROTACs (Proteolysis-Targeting Chimeras) take a different approach: rather than inhibiting a protein, they direct the cellular protein degradation machinery to destroy it. A PROTAC molecule is bifunctional — one end binds the target protein of interest (POI), the other binds an E3 ubiquitin ligase. When the PROTAC bridges the two, the E3 ligase tags the POI with ubiquitin, flagging it for proteasomal degradation.
Key advantages over traditional inhibitors: (1) catalytic mechanism — one PROTAC molecule can degrade multiple copies of the target, requiring lower drug concentrations; (2) access to previously “undruggable” proteins that lack a well-defined active site; (3) potential to overcome resistance mutations that render inhibitors ineffective; (4) complete elimination of protein rather than partial inhibition. Multiple PROTACs are in Phase II/III clinical trials as of 2026. Molecular glues are a related but conceptually distinct degrader approach — single-molecule agents that stabilize a ternary complex between target and E3 ligase. The compound CC-92480 (mezigdomide) and related compounds are examples in clinical development.
Small Molecule Analytical Testing
Key analytical methods for small molecule drug characterization and quality control:
- LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): The primary platform for potency (assay), impurity profiling, and metabolite identification. Provides high sensitivity, specificity, and quantitative accuracy for complex matrices, including plasma, tissue, and formulated products.
- HPLC with UV-Vis detection: Routine potency assay and impurity profiling per USP and ICH Q3A/Q3B guidelines. Dissolution testing for solid oral dosage forms uses HPLC to quantify drug release over time.
- NMR and HRMS: Structural confirmation of new chemical entities; impurity structure elucidation.
- DSC / XRPD: Differential scanning calorimetry and X-ray powder diffraction for polymorphism assessment — critical since different crystal forms of the same drug can have different bioavailability and stability profiles.
Peptide Drugs — GLP-1 Agonists and the Peptide Renaissance
Peptide drugs occupy a pharmacological middle ground between classical small molecules and protein biologics. They are typically 2–50 amino acids in length, synthesized by solid-phase peptide synthesis (SPPS) or semi-synthetic modification rather than cell culture, but their molecular targets and mechanisms often resemble those of biologics — high selectivity, receptor binding, and signaling pathway modulation. The global pharmaceutical market has been transformed by peptide drugs, most strikingly by the GLP-1 receptor agonists.
GLP-1 Receptor Agonists: The World’s Dominant Drug Class
Glucagon-like peptide-1 (GLP-1) receptor agonists — principally semaglutide (Ozempic for T2 diabetes, Wegovy for obesity; Novo Nordisk) and tirzepatide (Mounjaro for T2 diabetes, Zepbound for obesity; Eli Lilly) — are, as of 2025-2026, the world’s highest-revenue pharmaceutical products. Ozempic alone generated more than DKr120 billion (~$18.59 billion) in global sales in 2024. The GLP-1 agonists market is projected at $64.42 billion in 2025, growing to $170.75 billion by 2033 (CAGR 13%).
Semaglutide is a synthetic 34-amino acid GLP-1 analog modified with two key changes from native GLP-1: an amino acid substitution at position 8 (Aib substitution) to resist DPP-4 degradation, and a C18 fatty diacid chain attached via a hydrophilic linker to albumin-binding to extend half-life to approximately 7 days (enabling once-weekly injection or once-daily oral dosing). Tirzepatide is a dual GIP and GLP-1 receptor agonist, further extending the pharmacological reach of peptide therapeutics. See our dedicated testing guides: semaglutide testing and analysis, and tirzepatide testing.
Large Molecules: Biologics
Biologics are complex, high molecular weight therapeutics derived from or produced using living cells. They include monoclonal antibodies, recombinant proteins, hormones, enzymes, vaccines, cell therapies, and gene therapies. Unlike small molecules, biologics cannot be completely characterized by a single chemical formula — they are heterogeneous populations of molecules with natural variability in glycosylation, charge variants, and higher-order structure, all of which can affect safety and efficacy.
Monoclonal Antibodies (mAbs)
Monoclonal antibodies — engineered IgG proteins (~150 kDa) that bind with high affinity and specificity to a single target antigen — have been the dominant biologic drug class by revenue. Trastuzumab (Herceptin), adalimumab (Humira), pembrolizumab (Keytruda), rituximab (Rituxan), and dozens of others target cancer antigens, inflammatory cytokines, and checkpoint proteins. mAb manufacturing involves mammalian cell culture (typically Chinese hamster ovary [CHO] cells), extensive downstream purification (Protein A chromatography, polishing steps), and formulation in stabilized protein solutions. Potency testing for biopharmaceuticals — verifying biological activity rather than just chemical identity — is a defining feature of biologic QC.
Biologic Analytical Testing
Biologics require a fundamentally different analytical toolkit from small molecules:
- SEC-HPLC (Size Exclusion Chromatography): Measures protein aggregation and fragmentation. Aggregates are a critical safety concern, potentially triggering immune responses.
- DLS (Dynamic Light Scattering): Particle size distribution, complementing SEC for aggregate detection.
- IEF / Charge variant analysis (CEX-HPLC, cIEF): Maps charge heterogeneity from deamidation, glycosylation, and processing variants.
- Glycan analysis (HILIC-HPLC, LC-MS): Glycosylation pattern critically affects mAb Fc effector function (ADCC, CDC) and half-life.
- Cell-based potency assays: Measure biological activity (receptor binding, cell killing, reporter gene activation) — the regulatory gold standard per 21 CFR 610.10 and ICH Q6B.
- Endotoxin testing (LAL assay, USP <85>): Bacterial endotoxins cause fever/septic shock; rigorously controlled in parenteral biologics.
- Host cell protein (HCP) and host cell DNA assays: Process-related impurities from the production cell line that must be removed to acceptable limits.
Antibody-Drug Conjugates (ADCs): Bridging Small and Large Molecules
ADCs represent the most commercially successful pharmacological bridge between small and large molecule pharmacology. As of mid-2025, 18 ADCs have received global regulatory approval, with a total of 15 currently approved in the US. The ADC market grew from approximately $6.48 billion in 2024 to $7.55 billion in 2025, projected at ~$16 billion by 2030 (CAGR 16.24%). The commercial success of trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo) — with its unprecedented activity across multiple HER2-expressing tumor types — has redefined possibilities in oncology and demonstrated what a third-generation ADC can achieve.
ADC Structure: Three Critical Components
- Antibody (targeting component): A monoclonal antibody (typically IgG1) engineered to bind specifically to a tumor-associated surface antigen. The antibody determines tumor targeting, biodistribution, half-life, and Fc effector function. Over 80% of clinical ADC candidates are currently evaluated in solid tumors.
- Chemical linker: Connects the antibody to the cytotoxic payload and must be sufficiently stable in systemic circulation to prevent premature payload release while delivering reliable cleavage within the tumor cell. Cleavable linkers (enzymatically cleavable by lysosomal cathepsins; pH-sensitive) enable bystander killing of adjacent tumor cells after payload release. Non-cleavable linkers release payload only after complete antibody lysosomal degradation — more stable, but no bystander effect.
- Cytotoxic payload (small molecule drug): Highly potent cytotoxic agents with IC50s in the picomolar to nanomolar range. Common payload classes: auristatins (MMAE, MMAF — microtubule inhibitors; used in brentuximab vedotin); maytansinoids (DM1, DM4 — also microtubule inhibitors; used in ado-trastuzumab emtansine/Kadcyla); calicheamicins (DNA strand-breaking; gemtuzumab ozogamicin, inotuzumab ozogamicin); camptothecin analogs (topoisomerase I inhibitors — DXd used in trastuzumab deruxtecan/Enhertu; exatecan in sacituzumab govitecan).
Drug-to-Antibody Ratio (DAR) — The Critical ADC Quality Attribute
The Drug-to-Antibody Ratio (DAR) — the average number of cytotoxic payload molecules conjugated to each antibody — is the most distinctive critical quality attribute (CQA) of ADCs. Too few payload molecules (low DAR) reduces potency; too many (high DAR) increases systemic toxicity, reduce antibody stability, and shortens circulation half-life. Most approved ADCs have target DARs in the range of 2–8. Hydrophobic interaction chromatography (HIC-HPLC) and mass spectrometry are the primary methods for DAR determination. Non-site-specific conjugation produces heterogeneous ADC mixtures with a distribution of DAR values; site-specific conjugation technologies (thio-mAbs, unnatural amino acid incorporation) produce more homogeneous products with better-defined pharmacology.
Other key ADC analytical tests: free payload quantification (residual unconjugated cytotoxin — a safety critical impurity); conjugation site analysis by peptide mapping; aggregation (SEC-HPLC); antibody potency and binding affinity; and payload potency. API manufacturing and testing provide further context on the analytical platform supporting pharmaceutical product development.
mRNA Therapeutics
mRNA (messenger RNA) therapeutics deliver synthetic instructions directly into the patient’s cells, directing the cell’s ribosomes to produce a therapeutic protein of interest. The transformative commercial proof-of-concept was the Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines (Spikevax and Comirnaty) — the first mRNA products approved by any regulatory authority, authorized in 2020–2021, and providing the first real-world demonstration of mRNA technology at a population scale.
mRNA manufacturing is fundamentally different from biologic protein production: mRNA is synthesized cell-free, using enzymatic in vitro transcription (IVT) from a DNA template. This eliminates the need for cell culture, enables faster manufacturing timelines, and allows rapid sequence modification — a key advantage demonstrated during COVID-19 variant adaptations. The synthesized mRNA is encapsulated in lipid nanoparticles (LNPs) for delivery; LNPs protect mRNA from nuclease degradation and facilitate cellular uptake and endosomal escape.
Applications expanding beyond vaccines: cancer neoantigen vaccines (the personalized mRNA-4157/V940 from Merck and Moderna targets unique patient-specific tumor mutations; in Phase III for melanoma as adjuvant therapy); protein replacement for metabolic/rare diseases; and immune oncology approaches. The analytical characterization of mRNA drug products includes: integrity (capillary gel electrophoresis or Bioanalyzer for RNA integrity number); concentration (ddPCR, fluorimetry); capping efficiency; poly-A tail length; sequence confirmation; residual DNA template quantification; and LNP characterization (particle size by DLS, encapsulation efficiency, cryo-TEM morphology).
Oligonucleotide Therapeutics: siRNA and Antisense Oligonucleotides (ASOs)
Oligonucleotide drugs are short synthetic nucleic acid sequences (typically 15–30 bases, molecular weight ~7,000–25,000 Da) designed to interact with specific RNA sequences — mRNA, pre-mRNA, or regulatory RNA — to modulate gene expression. Produced by solid-phase synthesis (like small molecules), they target RNA with the precision of biologics. Two main classes have achieved clinical and commercial success:
siRNA (Small Interfering RNA)
siRNAs are double-stranded RNA molecules that exploit the endogenous RNA interference (RNAi) pathway: the siRNA loads into the RISC (RNA-induced silencing complex), which then uses the guide strand to find and cleave complementary target mRNA, reducing protein expression. First FDA-approved siRNA: patisiran (ONPATTRO, Alnylam, 2018) for hereditary transthyretin-mediated amyloidosis — delivered by LNP to the liver. Inclisiran (Leqvio, Novartis/Alnylam, 2021) targets PCSK9 mRNA to reduce LDL cholesterol — with only twice-yearly subcutaneous injection (GalNAc-conjugated hepatic delivery), a significant compliance advantage over weekly or biweekly alternatives.
Antisense Oligonucleotides (ASOs)
ASOs are single-stranded modified DNA or RNA sequences that bind to complementary mRNA or pre-mRNA by Watson-Crick base pairing. Depending on design, they can: recruit RNase H to degrade the target transcript; block ribosome translation; or modulate pre-mRNA splicing. Nusinersen (Spinraza, Biogen, 2016) — intrathecally administered ASO that corrects aberrant splicing in the SMN2 gene — transformed the treatment of spinal muscular atrophy. ASOs are particularly powerful for diseases caused by splicing defects or where a partially functional protein splice variant can be upregulated.
Oligonucleotide analytics: sequence confirmation by mass spectrometry (oligonucleotide mapping); purity by ion-pair reversed-phase HPLC or CGE; N-1 and other process impurities; residual synthesis reagents; endotoxin; and particle characterization for nanoparticle-formulated oligonucleotides.
Biosimilars: The Post-Patent Biologic Landscape
As biologics developed in the 1990s–2000s reach the end of their patent protection periods, a major market has developed for biosimilars — biological products that are highly similar to an approved reference biologic. Unlike generic small molecule drugs (which are chemically identical to their reference), biologics cannot be truly identical due to inherent variability in biological manufacturing processes. The FDA approval pathway for biosimilars (351(k) abbreviated BLA) requires demonstration of biosimilarity through a comprehensive “totality of evidence” approach: extensive physicochemical analytical comparability, functional comparability (binding, potency), pharmacokinetic/pharmacodynamic studies, and clinical immunogenicity data.
Major biologic patent expirations have driven rapid biosimilar growth: adalimumab (Humira) faces more than a dozen biosimilar competitors; trastuzumab, bevacizumab, and rituximab biosimilars are established markets. With semaglutide’s core patent expiring in 2026 in key markets, including China and India, the first major GLP-1 peptide biosimilar wave is beginning. Demonstrating biosimilarity for a complex glycoprotein mAb is analytically demanding — glycan mapping, charge variant profiles, SEC profiles, and cell-based potency all must fall within defined comparability margins. Potency testing for biopharmaceuticals is particularly central to biosimilar demonstration programs.
Shared Development Framework: From Discovery to Approval
Across all modalities, pharmaceutical development follows a broadly consistent framework — though with significant modality-specific variations in timeline, cost, and attrition rate. The total development timeline from discovery to approval averages 10–15 years, and costs typically exceed $1 billion per approved drug when accounting for failure costs.
- Target identification and validation: Establishing that a specific gene, protein, RNA, or signaling pathway is causally involved in disease and represents a druggable target. Genetic validation (GWAS, CRISPR knockouts) now plays a central role.
- Lead discovery: HTS of compound libraries (small molecules); phage display/hybridoma (antibodies); rational design (oligonucleotides, PROTACs); computational design (mRNA, siRNA). Fragment-based drug discovery and AI-assisted molecular design are accelerating hit identification for small molecules.
- Lead optimization: Iterative ADME/PK profiling, safety screening, and potency optimization. Lipinski’s Rule of Five guides small-molecule oral drug optimization.
- Preclinical development: GLP toxicology studies in two species, pharmacokinetics, pharmacodynamics, genotoxicity (for small molecules), immunogenicity (for biologics), manufacturing scale-up, and IND-enabling analytical method development.
- IND (Investigational New Drug) application: Filed with the FDA (or equivalent) to enable human clinical trials.
- Phase I–III clinical trials: Dose escalation/safety (Phase I) → efficacy signal and dose finding (Phase II) → pivotal efficacy and safety (Phase III). Approximate success rates: Phase I ~60%; Phase II ~35%; Phase III ~65%; FDA approval from Phase III ~90%.
- NDA (New Drug Application) / BLA (Biologics License Application): Small molecules and most peptides file NDA; biologics (mAbs, recombinant proteins, vaccines, gene/cell therapies, ADCs, most oligonucleotides) file BLA. NDAs and BLAs have different evidentiary requirements; biological products under BLAs have a higher bar for demonstrating safety and efficacy across all aspects of manufacturing and control. See also our guide to USP standards and testing applications.
- Post-approval pharmacovigilance and REMS: Ongoing safety monitoring; some drugs require Risk Evaluation and Mitigation Strategies (REMS) for high-risk biologics and small molecules.
Finding Contract Laboratories for Pharmaceutical Drug Development
The analytical, preclinical, and quality testing needs of pharmaceutical drug development span a broad and specialized range of capabilities. ContractLaboratory.com connects drug developers, CDMOs, CROs, and quality teams at every stage of development with accredited pharmacology and drug development laboratories and pharmaceutical and biopharmaceutical testing partners. Related resources: API manufacturing and testing; biopharmaceutical potency testing; stability studies; in vivo and in vitro testing.
Frequently Asked Questions
An ADC is a hybrid drug that combines three components: a monoclonal antibody (which provides tumor targeting via specific antigen binding), a cytotoxic small molecule payload (a highly potent cell-killing agent), and a chemical linker that connects them. A standard monoclonal antibody relies on its own biological mechanisms (blocking a signaling receptor, recruiting immune cells, or activating complement) to kill cancer cells. An ADC uses the antibody for targeted delivery, then releases a potent cytotoxin inside the tumor cell — combining the specificity of an antibody with the killing power of chemotherapy while minimizing systemic toxicity. As of mid-2025, 18 ADCs have been approved globally, making them one of the fastest-growing drug categories in oncology.
A New Drug Application (NDA) is filed with the FDA for small molecule drugs; a Biologics License Application (BLA) is filed for biological products, including monoclonal antibodies, recombinant proteins, vaccines, gene and cell therapies, and most antibody-drug conjugates and oligonucleotide drugs. The key difference is the regulatory framework: NDAs are governed by the FD&C Act, while BLAs are governed by the Public Health Service (PHS) Act, Section 351. BLAs require demonstration of manufacturing consistency across all aspects of the biological production process, including cell line characterization, fermentation, purification, and analytical comparability — a substantially higher and broader evidentiary bar than NDAs in many ways. Biological products approved under BLAs are subject to lot-release testing by the manufacturer before each batch is distributed.
Lipinski’s Rule of Five is a set of guidelines published by Christopher Lipinski (Pfizer) in 1997 for predicting whether a drug candidate is likely to be orally bioavailable in humans. A small molecule is predicted to have acceptable oral absorption if it satisfies most of these criteria: molecular weight ≤500 Daltons; calculated logP ≤5 (lipophilicity); number of hydrogen bond donors ≤5; number of hydrogen bond acceptors ≤10. Compounds that violate two or more of these rules statistically have poor oral bioavailability. The rule applies specifically to passive transcellular absorption and does not apply to compounds intended for IV administration, transporter substrates, or biologics. It is one of the most widely used tools in medicinal chemistry for filtering compound libraries and guiding lead optimization decisions.
A biosimilar is a biological product that is highly similar — but not identical — to an FDA-approved reference biologic whose patent has expired. A generic drug, by contrast, is chemically identical to its reference small molecule drug. Biosimilars cannot be identical to their reference products because biologics are produced by living cells and inherently have some manufacturing variability in glycosylation patterns, charge variants, and higher-order structure. FDA approval of a biosimilar under the 351(k) abbreviated BLA pathway requires demonstrating ‘biosimilarity’ through extensive analytical characterization, functional comparability, pharmacokinetic studies, and clinical immunogenicity data. Interchangeability — which allows a pharmacist to substitute a biosimilar for the reference biologic without prescriber intervention — requires additional clinical switching study data.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are synthetic peptide analogs that activate the glucagon-like peptide-1 receptor — a G protein-coupled receptor — to enhance insulin secretion, reduce glucagon, slow gastric emptying, and suppress appetite. Pharmacologically, they occupy a borderland between small molecules and biologics. They are made by solid-phase peptide synthesis (like small molecules, not cell culture), but their molecular weights (~4,000 Da for semaglutide) exceed Lipinski’s 500 Da limit, and they require injection or specialized oral formulations. The GLP-1 agonist market reached approximately $64 billion in 2025 and is one of the fastest-growing in pharmaceutical history.
Both siRNA and ASOs are short synthetic oligonucleotides that work by binding to specific RNA sequences to modulate gene expression. The key differences: siRNA is double-stranded RNA that loads into the RISC complex and cleaves the complementary target mRNA via the RNAi pathway, typically achieving potent and long-lasting gene silencing (weeks to months). ASOs are single-stranded modified DNA or RNA sequences that can work through multiple mechanisms — RNase H-mediated target mRNA degradation (most common for gene silencing), splice-switching to correct aberrant splicing, or translation blocking. siRNAs are primarily delivered to the liver via LNPs or GalNAc conjugates; ASOs can reach the CNS via intrathecal injection (enabling neurological applications). Both have distinct chemical modification strategies to resist nuclease degradation — phosphorothioate backbones, 2′-fluoro modifications, locked nucleic acids (LNA) — that are critical quality attributes tested by mass spectrometry.
Traditional small-molecule drugs work by occupying the active site of a target protein and blocking its function (inhibition). PROTACs (Proteolysis-Targeting Chimeras) take a fundamentally different approach: instead of inhibiting the target, they redirect the cell’s protein degradation machinery to destroy it. A PROTAC molecule has two binding domains connected by a linker — one end binds the target protein, the other binds an E3 ubiquitin ligase enzyme. When both bind simultaneously, the E3 ligase attaches ubiquitin tags to the target protein, marking it for destruction by the 26S proteasome. The key advantage: PROTACs act catalytically (one molecule can degrade multiple copies of the target), can access ‘undruggable’ proteins lacking traditional active sites, and can overcome resistance mutations that prevent inhibitor binding. Multiple PROTACs are in Phase II/III clinical trials as of 2026.
Conclusion
The pharmaceutical modality landscape of 2026 is far more diverse than the small molecule vs. biologic binary that defined the field for most of the twentieth century. ADCs bridge both worlds with 18 global approvals and a growing pipeline. mRNA therapeutics demonstrated pandemic-scale manufacturing capability and are now advancing into cancer and rare disease. Oligonucleotides (siRNA and ASO) enable RNA-level intervention with approved products treating genetic diseases from transthyretin amyloidosis to spinal muscular atrophy. PROTACs are rewriting what small molecule inhibitors can achieve. GLP-1 agonists — peptide drugs at the interface of chemistry and biology — have become the world’s dominant commercial pharmaceutical class. And biosimilars are building a sustainable market from the patent cliffs of the first biologic revolution. Understanding each modality’s distinct pharmacology, development pathway, and analytical testing requirements is essential for drug developers and their laboratory partners navigating this expanded landscape.
ContractLaboratory.com connects drug developers, CMDOs, CROs, and quality teams with accredited pharmacology and drug development laboratories and pharmaceutical and biopharmaceutical testing partners across all modalities. Submit a testing request or contact our team.